Esflurbiprofen

Esflurbiprofen was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Sep 28, 2015. It was developed by Taisho and marketed by Taisho and Teijin as Loqoa® in Japan.

Esflurbiprofen is a cyclooxygenase (COX) inhibitor indicated for the treatment of osteoarthritis pain and inflammation.

Loqoa® is available as a patch formulation, containing 40 mg of Esflurbiprofen. The recommended dose is applied to the lesion area once daily. Do not apply more than two patches simultaneously.

General Information

Update Date:2016-05-17

Drug Name:
Esflurbiprofen
Research Code:
BTS-24332; SFPP; TT-063
Trade Name:
Loqoa®
MOA:
COX inhibitor
Indication:
Osteoarthritis (OA)
Status:
Approved
Company:
Taisho (Originator) , Teijin
Sales:
$3.3 Million (Y2015)
ATC Code:
Approved Countries or Area

Update Date:2016-01-28

Approval Date Approval Type Trade Name Indication Dosage Form Strength Company Review Classification
2015-09-28 First approval Loqoa Osteoarthritis (OA) Patch Eq. 40 mg Esflurbiprofen Taisho
Chemical Structure

Update Date:2016-01-22

Molecular Weight 244.26
Formula C15H13FO2
CAS No. 51543-39-6 (Esflurbiprofen);
Chemical Name (S)-2-fluoro-α-methyl-4-biphenylacetic acid
Esflurbiprofen (Free Acid/Base)Parameters:
MW HD HA FRB* PSA* cLogP*
244.26 1 2 3 37.3 3.656±0.377
*:Calculated by ACD/Labs software V11.02.
Synthesis & Impurities

Update Date:2016-02-21


1. US4188491A.


1. WO2015145163A1.

Impurity database is being updated!